リケラボ論文検索は、全国の大学リポジトリにある学位論文・教授論文を一括検索できる論文検索サービスです。

リケラボ 全国の大学リポジトリにある学位論文・教授論文を一括検索するならリケラボ論文検索大学・研究所にある論文を検索できる

リケラボ 全国の大学リポジトリにある学位論文・教授論文を一括検索するならリケラボ論文検索大学・研究所にある論文を検索できる

大学・研究所にある論文を検索できる 「Prognostic impact of transcardiac gradient of follistatin-like 1 reflecting hemodynamics in patients with dilated cardiomyopathy」の論文概要。リケラボ論文検索は、全国の大学リポジトリにある学位論文・教授論文を一括検索できる論文検索サービスです。
リケラボ

コピーが完了しました

URLをコピーしました

論文の公開元へ論文の公開元へ
書き出し

Prognostic impact of transcardiac gradient of follistatin-like 1 reflecting hemodynamics in patients with dilated cardiomyopathy

大石, 英生 名古屋大学

2022.07.01

概要

Background: Follistatin-like 1 (FSTL1) is a myocyte-secreted glycoprotein that could play a role in myocardial maintenance in response to harmful stimuli. We investigated the association between serum FSTL1 levels, especially focused on transcardiac gradient and the hemodynamics, to explore the prognostic impact of FSTL1 levels in patients with dilated cardiomyopathy (DCM).

Methods: Thirty-two ambulatory patients with DCM (23 men; mean age 59 years) were prospectively enrolled. Blood samples were simultaneously collected from the aortic root (Ao), coronary sinus (CS), as well as from the peripheral vein during cardiac catheterization in stable conditions. The transcardiac gradient of FSTL1 was calculated by the difference between serum FSTL1 levels of CS and Ao (FSTL1CS-Ao). Patients were divided into two groups based on the median of FSTL1CS-Ao: Low FSTL1CS-Ao group,< 0 ng/mL; High FSTL1CS-Ao group, ≥0 ng/mL. Cardiac events were defined as a composite of cardiac deaths and hospitalizations for worsening heart failure.

Results: Mean left ventricular ejection fraction and median plasma B-type natriuretic peptide levels were 30.9% and 92.3 pg/mL, respectively. FSTL1CS-Ao was negatively correlated with pulmonary capillary wedge pressure (r = -0.400, p = 0.023). Kaplan-Meier survival analysis showed that event-free survival rate was significantly lower in the Low FSTL1CS-Ao group than in the High FSTL1CS-Ao group (p = 0.013). Cox regression analyses revealed that the transcardiac gradient of FSTL1 was an independent predictor for cardiac events. Receiver operating characteristic curve analysis showed that the cut-off value of FSTL1CS-Ao for the prediction of cardiac events was -4.09 ng/mL with sensitivity of 82% and specificity of 86% (area under the curve, 0.87).

Conclusions: Fifty percent of patients had negative transcardiac gradient of FSTL1. Reduced transcardiac gradient of FSTL1 might be a novel prognostic predictor in DCM patients with impaired hemodynamics.

論文の公開元へ

この論文で使われている画像

関連論文

関連論文をもっと見る

参考文献

[1] Stolfo D, Albani S, Savarese G, Barbati G, Ramani F, Gigli M, et al. Risk of sudden cardiac death in New York Heart Association class I patients with dilated cardiomyopathy: a competing risk analysis. Int J Cardiol 2020;307:75–81. doi:10.1016/j.ijcard.2020.02.025.

[2] Onoue K, Saito Y. New treatment for myocardial diseases. J Cardiol 2021;77:620–5. doi:10.1016/j.jjcc.2020.10.016.

[3] Fuster V, Gersh BJ, Giuliani ER, Tajik AJ, Brandenburg RO, Frye RL. The natural history of idiopathic dilated cardiomyopathy. Am J Cardiol 1981;47:525–31. doi:10.1016/0002-9149(81)90534-8.

[4] Castelli G, Fornaro A, Ciaccheri M, Dolara A, Troiani V, Tomberli B, et al. Improving survival rates of patients with idiopathic dilated cardiomyopathy in Tuscany over 3 decades: impact of evidence-based management. Circ Hear Fail 2013;6:913–21. doi:10.1161/CIRCHEARTFAILURE.112.000120.

[5] Merlo M, Pivetta A, Pinamonti B, Stolfo D, Zecchin M, Barbati G, et al. Longterm prognostic impact of therapeutic strategies in patients with idiopathic dilated cardiomyopathy: changing mortality over the last 30 years. Eur J Heart Fail 2014;16:317–24. doi:10.1002/ejhf.16.

[6] Ushigome R, Sakata Y, Nochioka K, Miyata S, Miura M, Tadaki S, et al. Improved long-term prognosis of dilated cardiomyopathy with implementation of evidenced-based medication: report from the CHART studies. Circ J 2015;79:1332–41. doi:10.1253/circj.CJ-14-0939.

[7] Halliday BP, Gulati A, Ali A, Newsome S, Lota A, Tayal U, et al. Sex- and agebased differences in the natural history and outcome of dilated cardiomyopathy. Eur J Heart Fail 2018;20:1392–400. doi:10.1002/ejhf.1216.

[8] Ahn MS, Kim JB, Joung B, Lee MH, Kim SS. Prognostic implications of fragmented QRS and its relationship with delayed contrast-enhanced cardiovascular magnetic resonance imaging in patients with non-ischemic dilated cardiomyopathy. Int J Cardiol 2013;167:1417–22. doi:10.1016/j.ijcard.2012.04.064.

[9] Tang WHW, Francis GS, Morrow DA, Newby LK, Cannon CP, Jesse RL, et al. National academy of clinical biochemistry laboratory medicine practice guidelines: clinical utilization of cardiac biomarker testing in heart failure. Clin Biochem 2008;41:210–21. doi:10.1016/j.clinbiochem.2007.07.002.

[10] Tsutamoto T, Wada A, Hayashi M, Tsutsui T, Maeda K, Ohnishi M, et al. Relationship between transcardiac gradient of endothelin-1 and left ventricular remodelling in patients with first anterior myocardial infarction. Eur Heart J 2003;24:346–55. doi:10.1016/S0195-668X(02)00420-7.

[11] Ellims AH, Taylor AJ, Mariani JA, Ling LH, Iles LM, Maeder MT, et al. Evaluating the utility of circulating biomarkers of collagen synthesis in hypertrophic cardiomyopathy. Circ Heart Fail 2014;7:271–8. doi:10.1161/CIRCHEARTFAILURE. 113.000665.

[12] Ohashi Y, Kawashima S, Mori T, Terashima M, Ichikawa S, Ejiri J, et al. Soluble CD40 ligand and interleukin-6 in the coronary circulation after acute myocardial infarction. Int J Cardiol 2006;112:52–8. doi:10.1016/j.ijcard.2005.09.051.

[13] Unno K, Shibata R, Izawa H, Hirashiki A, Murase Y, Yamada T, et al. Adiponectin acts as a positive indicator of left ventricular diastolic dysfunction in patients with hypertrophic cardiomyopathy. Heart 2010;96:357–61. doi:10.1136/ hrt.2009.172320.

[14] El-Armouche A, Ouchi N, Tanaka K, Doros G, Wittköpper K, Schulze T, et al. Follistatin-like 1 in chronic systolic heart failure a marker of left ventricular remodeling. Circ Heart Fail 2011;4:621–7. doi:10.1161/CIRCHEARTFAILURE.110. 960625.

[15] Widera C, Horn-Wichmann R, Kempf T, Bethmann K, Fiedler B, Sharma S, et al. Circulating concentrations of follistatin-like 1 in healthy individuals and patients with acute coronary syndrome as assessed by an immunoluminometric sandwich assay. Clin Chem 2009;55:1794–800. doi:10.1373/clinchem.2009. 129411.

[16] Shimano M, Ouchi N, Nakamura K, Van Wijk B, Ohashi K, Asaumi Y, et al. Cardiac myocyte follistatin-like 1 functions to attenuate hypertrophy following pressure overload. Proc Natl Acad Sci U S A 2011;108:899–906. doi:10.1073/ pnas.1108559108.

[17] Ogura Y, Ouchi N, Ohashi K, Shibata R, Kataoka Y, Kambara T, et al. Therapeutic impact of follistatin-like 1 on myocardial ischemic injury in preclinical models. Circulation 2012;126:1728–38. doi:10.1161/CIRCULATIONAHA.112.115089.

[18] Seki M, Powers JC, Maruyama S, Zuriaga MA, Wu CL, Kurishima C, et al. Acute and chronic increases of circulating FSTL1 normalize energy substrate metabolism in pacing-induced heart failure. Circ Heart Fail 2018;11:1–12. doi:10.1161/CIRCHEARTFAILURE.117.004486.

[19] Lara-Pezzi E, Felkin LE, Birks EJ, Sarathchandra P, Panse KD, George R, et al. Expression of follistatin-related genes is altered in heart failure. Endocrinology 2008;149:5822–7. doi:10.1210/en.2008-0151.

[20] Lang RM, Badano LP, Mor-Avi V, Afilalo J, Armstrong A, Ernande L, et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging 2015;16:233–71. doi:10.1093/ehjci/jev014.

[21] Devereux RB, Alonso DR, Lutas EM, Gottlieb GJ, Campo E, Sachs I, et al. Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. Am J Cardiol 1986;57:450–8. doi:10.1016/0002-9149(86) 90771-X.

[22] Hiraiwa H, Okumura T, Sawamura A, Sugiura Y, Kondo T, Watanabe N, et al. The Selvester QRS score as a predictor of cardiac events in nonischemic dilated cardiomyopathy. J Cardiol 2018;71:284–90. doi:10.1016/j.jjcc.2017.09.002.

[23] Hayakawa S, Ohashi K, Shibata R, Takahashi R, Otaka N, Ogawa H, et al. Association of circulating follistatin-like 1 levels with inflammatory and oxidative stress markers in healthy men. PLoS ONE 2016;11:e0153619. doi:10.1371/ journal.pone.0153619.

[24] Matsuo S, Imai E, Horio M, Yasuda Y, Tomita K, Nitta K, et al. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis 2009;53:982–92. doi:10.1053/j.ajkd.2008.12.034.

[25] Ogawa H, Ohashi K, Ito M, Shibata R, Kanemura N, Yuasa D, et al. Adipolin/CTRP12 protects against pathological vascular remodelling through suppression of smooth muscle cell growth and macrophage inflammatory response. Cardiovasc Res 2020;116:237–49. doi:10.1093/cvr/cvz074.

[26] Le Luduec JB, Condamine T, Louvet C, Thebault P, Heslan JM, Heslan M, et al. An immunomodulatory role for follistatin-like 1 in heart allograft transplantation. Am J Transplant 2008;8:2297–306. doi:10.1111/j.1600-6143.2008.02398.x.

[27] Miyabe M, Ohashi K, Shibata R, Uemura Y, Ogura Y, Yuasa D, et al. Musclederived follistatin-like 1 functions to reduce neointimal formation after vascular injury. Cardiovasc Res 2014;103:111–20. doi:10.1093/cvr/cvu105.

参考文献をもっと見る

全国の大学の
卒論・修論・学位論文
を
一発検索！

この論文の関連論文を見る